Healthcare Industry News: NeuroBlate
News Release - July 19, 2016
Monteris Medical Announces Appointment Of Martin J. Emerson As President and Chief Executive OfficerPLYMOUTH, Minn., July 19, 2016 -- (Healthcare Sales & Marketing Network) -- Monteris Medical today announced that its Board of Directors has appointed Martin J. Emerson as its President and Chief Executive Officer effective immediately. Monteris Medical is a privately held leader in the market for minimally invasive, MRI-guided laser ablation systems for treating brain lesions. Mr. Emerson has over 25 years of medical device industry experience including CEO positions with both private and public companies.
Greg Barrett, Chairman of the Monteris Medical Board of Directors, commented, "We are pleased and privileged to have an executive with Marty Emerson's experience and track record take over the reins at Monteris Medical. He has both the leadership and market knowledge necessary to build Monteris into a world-class medical device company."
For the past eight years, Mr. Emerson served as President and CEO of Galil Medical, a privately held market leader in cryoablation systems. During his tenure, Galil's investment in technology and clinical research led the way to a ten-fold increase in the company's sales within the interventional oncology market. Galil was acquired in June 2016 by BTG plc. From 2000 to 2008, Mr. Emerson held various management positions including the role of President and CEO with American Medical Systems (AMS), a publicly traded urology and gynecology device company with sales of more than $500 million annually. Previously, Mr. Emerson also held various domestic and international management positions with Boston Scientific Corporation and Baxter International. Mr. Emerson currently serves on the Board of Directors for Vascular Solutions, Tepha Medical Devices and Incisive Surgical.
Martin Emerson added, "I would like to thank the Monteris Board of Directors for the opportunity to lead a company with such exciting technology offering minimally invasive surgical alternatives to patients with brain tumors and epilepsy. I look forward to working with the talented Monteris management team to meet the high expectations of the company's investors, physicians and their patients."
About Monteris® and the NeuroBlate® System
Monteris® Medical is a privately held company that develops and markets innovative MRI-guided, laser-based systems for the ablation of brain lesions. The Monteris NeuroBlate® System includes the Mini-Bolt, the only minimally invasive cranial access system that enables a robotic interface for the precise and safe delivery of laser energy. Since receiving FDA clearance in 2013, NeuroBlate has been used in more than 800 patient procedures across 35 installed systems in the U.S. and Canada.
The NeuroBlate® System is a tool (as opposed to a "treatment") and is not intended to treat any specific disease. Physicians should use their clinical judgment and experience when deciding whether to use NeuroBlate®.
For more information about Monteris and full prescribing information for the NeuroBlate® System, please visit www.monteris.com.
Source: Monteris Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.